PRLD
Prelude Therapeutics Incorporated
Healthcare — Biotechnology
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Price History
Fundamentals
| Market Cap | $391.06M |
| P/E Ratio (TTM) | - |
| Forward P/E | -5.22 |
| EPS (TTM) | $-1.00 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -95.25% |
| Debt/Equity | 29.45 |
| Recommendation | None |
| Analyst Target | $8.00 |
| Analysts | 3 |
| Next Earnings | Aug 11, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 66.0 |
| Beta | 1.01 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $5.69 |
| 52-Week Low | $0.75 |
| 50-Day Avg | $4.39 |
| 200-Day Avg | $2.78 |
| Avg Volume | 498.1K |
| Volume | 543.3K |
Performance Analysis
BULLISHPRLD shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:27 UTC
Back to Screener Export Report